Parkinson's drug safety trial halted early
NCT ID NCT04976127
First seen Apr 25, 2026 · Last updated May 25, 2026 · Updated 7 times
Summary
This early-stage study tested a new drug called talineuren in 22 people with Parkinson's disease. The goal was to see if it is safe to give through a vein. The study was stopped early, and it focused on safety, not on curing the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Neurologisches Institut Konolfingen
Konolfingen, Canton of Bern, 3510, Switzerland
Conditions
Explore the condition pages connected to this study.